Alasdair Keith

2 months ago | onlinelibrary.wiley.com | Alasdair Keith |Elizabeth Sawyer |James Cole |Cheng Shang

1 INTRODUCTION Catabolism of exogenous haem by bacterial pathogens is typically mediated by a haem oxygenase (HO) via a process requiring three O2 molecules, and ultimately yielding regiospecific biliverdin and CO alongside the extracted Fe2+ ion (Lyles and Eichenbaum 2018; Maines and Kappas 1974; Unno et al. 2007; Wilks and Heinzl 2014; Wilks and Ikeda-Saito 2014). Many bacterial pathogens are facultatively anaerobic and can thus thrive under oxygen-depleted conditions (André et al.

Dec 11, 2024 | jbc.org | Meredith M. Keen |Alasdair Keith |Eric Ortlund

The abbreviations used are DMS (deep mutational scanning) Fab (fragment-antigen binding region) HDX (hydrogen-deuterium exchange) PMA (peptide microarrays) p-MHC (peptide-major histocompatibility complex) APC (antigen-presenting cell) SABR (signaling and antigen presenting bifunctional receptor) IEDB (immune epitope database & tools) MS EL (mass spectrometry-derived eluted ligand) EM-DMS (epitope mapping via deep mutational scanning) SSM (site-saturation mutagenesis library) CFU (colony...

Mar 19, 2024 | dx.doi.org | Alasdair Keith |Eva Přáda Brichtová |Jack Barber |David J Wales

Glucagon-like peptide-1 (GLP-1) is a peptide hormone comprising 30 or 31 amino acids. (1−3) As an incretin, GLP-1 stimulates a decrease in blood glucose levels and, thus, is of increasing importance within the pharmaceutical industry as a therapeutic agent for the treatment of type 2 diabetes and obesity. (4−6) Several GLP-1 analogues have been produced commercially. (7,8) Though currently in widespread use as an intravenous treatment, challenges remain with regard to its formulation.

Mar 19, 2024 | pubs.acs.org | Alasdair Keith |Eva Přáda Brichtová |Jack Barber |David J Wales

Glucagon-like peptide-1 (GLP-1) is a peptide hormone comprising 30 or 31 amino acids. (1−3) As an incretin, GLP-1 stimulates a decrease in blood glucose levels and, thus, is of increasing importance within the pharmaceutical industry as a therapeutic agent for the treatment of type 2 diabetes and obesity. (4−6) Several GLP-1 analogues have been produced commercially. (7,8) Though currently in widespread use as an intravenous treatment, challenges remain with regard to its formulation.

Aug 14, 2023 | pubs.rsc.org | Alasdair Keith |Elizabeth Sawyer |Yuhang Xie |George Biggs

Combining Experiment and Energy Landscapes to Explore Anaerobic Heme Breakdown in Multifunctional Hemoproteins To survive, many pathogens extract heme from their host organism and break down the porphyrin scaffold to sequester the Fe2+ ion via a heme oxygenase. Recent studies have revealed that certain pathogens can anaerobically degrade heme.